Ultragenyx Sells Priority Review Voucher for $210 Million

Ultragenyx Pharmaceutical said 7 October 2026 that it has agreed to sell a rare pediatric disease priority review voucher for $210 million, the latest data point in a secondary market that keeps a congressionally reauthorized incentive program liquid for sponsors who would rather have cash than a redeemable ticket. The voucher traces back to August's accelerated approval of Genglycos, Ultragenyx's first gene therapy.

What a priority review voucher actually buys

FDA's rare pediatric disease priority review voucher program rewards an approved treatment for a qualifying rare pediatric disease with a transferable voucher: the holder can redeem it on any future marketing application to cut that application's standard review clock to six months, or sell the voucher to a company that wants the faster review more than it wants to develop its own rare pediatric disease drug. Congress let the program lapse at the end of 2024 before reviving it in the Consolidated Appropriations Act, 2026, signed 3 February 2026, which extends FDA's authority to issue new vouchers through 30 September 2029. Ultragenyx's sale is a sign the secondary market reopened with the program: $210 million sits comfortably inside the $150 million-plus range recent sales — Rocket Pharmaceuticals' $180 million deal and SPARC's $195 million sale, both earlier in 2026 — have established as the going rate, well below the $350 million high-water mark United Therapeutics set selling a voucher to AbbVie in 2015, but far from the program's early-2025 uncertainty.

The gene therapy behind the voucher

FDA granted the underlying voucher alongside Genglycos' accelerated approval on 19 August 2026. Genglycos delivers a functional G6PC gene to liver cells via a one-time AAV8 vector infusion, intended to reduce the constant cornstarch regimen that patients with glycogen storage disease type Ia use to prevent dangerous drops in blood sugar. It is indicated for patients 8 and older, rests on a randomized, placebo-controlled trial following roughly 46 participants over 48 weeks, and carries a label contraindication for patients with known severe hepatic fibrosis or cirrhosis plus warnings for hypersensitivity reactions including anaphylaxis. Because the approval is accelerated, Ultragenyx must still supply two years of confirmatory data from 50 commercially treated patients and 20 untreated controls through its disease monitoring program.

Why the clawback and the antitrust clock matter

The NIH patent license obligation is a reminder that a voucher's headline price is not the sponsor's actual take: Ultragenyx's SEC filing puts the NIH share at 20% of gross proceeds, roughly $42 million, leaving about $168 million before transaction expenses on a $210 million sale. The Hart-Scott-Rodino waiting period — standard antitrust review for a transaction of this size — means the deal is agreed but not yet closed; Ultragenyx's release did not name the buyer, continuing a pattern in which voucher purchasers routinely stay anonymous. CFO Howard Horn framed the proceeds as non-dilutive capital for the company's rare-disease pipeline and its path to profitability, and said the company intends to sell its remaining Priority Review Voucher as well.

Frequently asked questions

What did Ultragenyx announce?

On 7 October 2026, Ultragenyx said it had entered a definitive agreement to sell a rare pediatric disease priority review voucher for $210 million. The buyer was not disclosed; closing is subject to Hart-Scott-Rodino clearance.

Where did the voucher come from?

FDA granted it alongside the 19 August 2026 accelerated approval of Genglycos (pariglasgene brecaparvovec-opnr/DTX401), a one-time AAV8 gene therapy for glycogen storage disease type Ia in patients 8 and older.

Does Ultragenyx keep the full $210 million?

No. A 2018 NIH patent license takes 20% of gross proceeds, about $42 million, leaving roughly $168 million before transaction expenses, per the company's SEC filing.

What will Ultragenyx do with the proceeds?

CFO Howard Horn said the sale provides non-dilutive capital for the rare-disease pipeline and supports the path to profitability. It is Ultragenyx's third PRV sale; the company has said it intends to sell a second voucher it still holds.